Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The uptake of nucleosides by transporters, such as SLC29A2, is essential for nucleotide synthesis by salvage pathways in cells that lack de novo biosynthetic pathways. Additionally we are shipping SLC29A2 Proteins (4) and many more products for this protein.
Showing 10 out of 40 products:
Cow (Bovine) Polyclonal SLC29A2 Primary Antibody for WB - ABIN2781572
Bone, Hammond: Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter. in American journal of physiology. Heart and circulatory physiology 2007
Human Polyclonal SLC29A2 Primary Antibody for IHC, WB - ABIN2781571
Owen, Lagpacan, Taylor, De La Cruz, Huang, Kawamoto, Johns, Stryke, Ferrin, Giacomini: Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. in Drug metabolism and disposition: the biological fate of chemicals 2005
Show all 2 Pubmed References
two novel functional splice variants of equilibrative nucleoside transporter 2 (ENT2), which are present at the nuclear envelope, were identified.
Results showed that both SLC29A1 (show SLC29A1 Antibodies) and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites.
Direct evidence for apical localization of ENT1 (show SLC29A1 Antibodies) and integral expression of ENT2 in intestinal epithelial cells.
Data suggest that SLC29A2 is localized to apical membrane of adult Sertoli cells. In contrast, SLC29A1 (show SLC29A1 Antibodies) is located on basolateral membrane of Sertoli cells; SLC29A1 (show SLC29A1 Antibodies) is primarily responsible for basolateral nucleoside uptake into Sertoli cells.
Data show that ENT1 (show SLC29A1 Antibodies), ENT2, ENT4 (show SLC29A4 Antibodies) and CNT3 (show SLC28A3 Antibodies) protein was detected on ovarian carcinoma cells in all effusions, with expression observed in 1-95% of tumor cells.
Studies show that ABCC4 (show ABCC4 Antibodies) and SLC29A2 expression were predictive of achieving CR, and the high expression of GSTP1 (show GSTP1 Antibodies) suggests that this may be a therapeutic target for relapsed AML (show RUNX1 Antibodies).
Equilibrative nucleoside transporters (hENT1, hENT2) together with adenosine kinase (show ADK Antibodies) and 5'-nucleotidase (show NT5E Antibodies) play a crucial role in the regulation of CFTR (show CFTR Antibodies) through an adenosine-dependent pathway in human airway epithelia.
Only a few endometrial carcinomas (15%) were found to be negative for hCNT1, but they all retained hENT1 and hENT2 expression.
the corresponding residues in TMs 1 (show SERINC3 Antibodies) and 11 of hENT1, hENT2, and CeENT1 are important for dipyridamole interactions and nucleoside transport.
The low overall genetic diversity in SLC29A2 makes it unlikely that variation in the coding region contributes significantly to clinically observed differences in drug response.
Data suggest that crosstalk pathway between ENT2 and alveolar epithelial Adora2b (show ADORA2B Antibodies) in lung protection during acute lung injury (ALI) opens possibilities for combined therapies targeted to this protein set.
Inosine and ENT-2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 (show ASGR1 Antibodies) cell line.
HIF-1alpha (show HIF1A Antibodies)-dependent repression of ENT2 increases mucosal adenosine signaling and attenuates hypoxia-associated inflammation of the intestine.
Ruminal infusion of starch hydrolysate increased duodenal and ileal expression ENT2 mRNA. Abomasal infusion increased ileal and jejunal ENT2 mRNA expression.
The uptake of nucleosides by transporters, such as SLC29A2, is essential for nucleotide synthesis by salvage pathways in cells that lack de novo biosynthetic pathways. Nucleoside transport also plays a key role in the regulation of many physiologic processes through its effect on adenosine concentration at the cell surface (Griffiths et al., 1997
hypothetical protein LOC394022
, solute carrier family 29 (nucleoside transporters), member 2
, equilibrative nucleoside transporter 2
, 36 kDa nucleolar protein HNP36
, delayed-early response protein 12
, equilibrative NBMPR-insensitive nucleoside transporter
, equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter
, hydrophobic nucleolar protein, 36 kDa
, hydrophobic nucleolar protein, 36kD
, nucleoside transporter, ei-type
, solute carrier family 29 member 2
, solute carrier family 29, member 2
, 36 kDa hydrophobic nucleolar protein
, delayed early response gene 12
, NBMPR-insensitive nucleoside transporter ei